Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
crispr
deals
fda
indiana blog main
indiana top stories
messenger rna
roche
startups
alzheimer's disease
amgen
amicus therapeutics
cancer immunotherapy
clinical study
What
bio
5
×
crispr
5
×
roundup
big
cas
ceo
today
acquisitions
albert
alliance
allogene
available
based
biggest
biosciences
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
calls
cancer
changing
cheaper
color
company
crime
days
departure
develop
diagnostics
diversity
drug
editas
exit
expects
faster
future
Language
unset
unknown
Current search:
biotech
×
bio
×
crispr
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More